To study the concept of seven Dravya in cause and subsequent development of Eka Kushtha and its principle management with special reference to blood letting with Jalauka

To study the concept of Sapta Dravya Samgrah in aetiopathogenesis of Eka Kushtha and its Saiddhantik Chikitsa (principle management) w.s.r. to Jalaukavacharna

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/06/043034

Enrollment

Registered

2022-06-06

Start date

Unknown

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L400- Psoriasis vulgaris

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients showing sign and symptoms of Eka Kushtha (psoriasis). 2) Age group 16-70 years should be included in the trial. 3) Patients willing for trial will be included in the study after obtaining detailed in formed consent.

Exclusion criteria

Exclusion criteria: a. Patients suffering from Anemia, Haemophillia A, Haemophillia B, Septic disorders, Allergic reaction to (Hirudin) active ingredient in leech saliva, Immunocompromised, Hypertension, Diabetes-mellitus, Hepatitis B. b. Patients below 16 year and above 70 year of age. C. Patients not willing for trial.

Design outcomes

Primary

Measure	Time frame
1. Area of Involvement- The body is divided into four sections - Head (10% of a persons skin), arms (20%), trunk (30%) and legs (40%). Each of these area is scored and then four scores are combined into final PASI. 2. Within each area the severity is estimated by three clinical signs: Erythema, Induration, Desquamation.Timepoint: 2 month	—

Secondary

Measure	Time frame
Cured: 100% relief in signs and symptoms. Marked improvement: More than 75% improvement in signs and symptoms will be recorded as marked improvement. Moderate improvement: 51% to 75% improvement in signs and symptoms will be considered as moderate improvement. Mild improvement: 25% to 50% improvement in sign and symptoms will be considered as mild improvement. No improvement: Less than 25% reduction in signs and symptoms will be noted as unchanged.Timepoint: 3month	—

Measure

Time frame

Cured: 100% relief in signs and symptoms. Marked improvement: More than 75% improvement in signs and symptoms will be recorded as marked improvement. Moderate improvement: 51% to 75% improvement in signs and symptoms will be considered as moderate improvement. Mild improvement: 25% to 50% improvement in sign and symptoms will be considered as mild improvement. No improvement: Less than 25% reduction in signs and symptoms will be noted as unchanged.Timepoint: 3month

—

Countries

India

Contacts

Public ContactDiksha ayri

Rajiv Gandhi Ayurvedic College and Hospital Paprola

satishgandharve@gmail.com7018241280

Outcome results